Journal
BRITISH JOURNAL OF CANCER
Volume 102, Issue 7, Pages 1137-1144Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/sj.bjc.6605612
Keywords
MKP-1; cetuximab; CRC; RAS; molecular marker
Categories
Funding
- Spanish Health Ministry Grant 'Fondo de Investigacion Sanitaria [PI061513, PS0901491, PS0901285, PJ091296]
- DIUE [RTICC 06/0020/19, 2009 SGR 321]
Ask authors/readers for more resources
BACKGROUND: The validation of KRAS mutations as a negative marker of response to anti-epidermal growth factor receptor (EGFR) antibodies has meant a seminal advance towards treatment individualisation of colorectal cancer (CRC) patients. However, as a KRAS wild-type status does not guarantee a response to anti-EGFR antibodies, a current challenge is the identification of other biomarkers of response. On the basis of pre-clinical evidence, we hypothesised that mitogen-activated protein kinase phosphatase-1 (MKP-1), a phosphatase that inactivates MAPKs, could be a mediator of resistance to anti-EGFR antibodies. METHODS: Tumour specimens from 48 metastatic CRC patients treated with cetuximab-based chemotherapy were evaluated for KRAS and BRAF mutational status and MKP-1 expression as assessed by immunohistochemistry. RESULTS: As expected, clinical benefit was confined to wild-type KRAS and BRAF patients. Mitogen-activated protein kinase phosphatase-1 was overexpressed in 16 patients (33%) and was not associated with patient baseline clinicopathological characteristics and KRAS mutational status. All patients with BRAF mutations (n = 3) had MKP-1 overexpression. Among KRAS wildtype patients, MKP-1 overexpressors had a 7% response rate (RR), whereas patients not overexpressing MKP-1 had a 44% RR (P = 0.03). Moreover, median time to progression was significantly longer in MKP-1 non-overexpressing patients (32 vs 13 weeks, P = 0.009). CONCLUSION: These results support the concept of MKP-1 as a promising negative marker of response to cetuximab-based treatment in CRC patients with wild-type KRAS. British Journal of Cancer (2010) 102, 1137-1144. doi:10.1038/sj.bjc.6605612 www.bjcancer.com Published online 16 March 2010 (C) 2010 Cancer Research UK
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available